A phase II trial found that T-VEC improved tumor resectability in 50% of patients, leading to early study discontinuation, with strong immune response activation and minimal side effects. Study: ...
Please provide your email address to receive an email when new articles are posted on . Patients with resectable melanoma who received T-VEC prior to surgery achieved better 5-year OS than those who ...
The oncolytic viral immunotherapy talimogene laherparepvec (T-VEC; Imlygic) was associated with a significant improvement in 5-year survival outcomes, including overall survival, compared with surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results